Table 3:
Overall Rate (%) of Adverse Events and Treatment Modifications with Immune Checkpoint Inhibitors
| Nivolumab13 | Pembrolizumab14 | Nivolumab + ipilimumab17 | Pembrolizumab + axitinib28 | Avelumb + Axitinib26 | Atezolizumab + bevacizumab20 | |
|---|---|---|---|---|---|---|
| Trial | CheckMate-025 | KEYNOTE-427 | CheckMate-214 | KEYNOTE-426 | JAVELIN RENAL 101 | IMmotion-151 |
| All Grade AEs | 78.5% | 80% | 97.4% | 98.4% | 99.5% | 91.3% |
| > Grade 3 AEs | 19% | 21.8% | 46.7% | 75.8% | 71.2% | 40.3% |
| Deaths | -- | 0.9% | 1.8% | 2.6% | 0.7% | 1.1% |
| % treatment discontinued due to AEs | 8% | 10.9% | 22% | 30.5% | 7.6% | 1.9% |
| % treated with high-dose glucorticoids for AEs | Not reported | 12.7% | 27.7% | Not reported | 11.1% | 16.6% |